Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Tazarotene is an acetylenic retinoid used for the topical treatment of mild to moderate acne, plaque psoriasis and signs of photoaging or sun-damaged skin (fine wrinkles, mottled skin pigmentation), acne vulgaris and plaque psoriasis.
As of the last update we found no published data on its excretion in breast milk.
Only 2-3% of the drug is absorbed transcutaneously and plasma levels are only 0.09 ng/ml, although this value is largely a function of the surface area treated. It should not be applied to more than 20% of the body surface area, as it increases systemic absorption. (Hale, Yaghi 2024, Butler 2014)
Given the potential mutagenic properties, infant skin should not come into contact with treated areas of maternal skin. It should not be applied to the breast so that the infant cannot ingest the product. (Gottlieb 2019)